Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer

Purpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment for metastatic colorectal cancer. Method...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff
Formaat: Artikel
Taal:English
Gepubliceerd in: Elsevier 2024-01-01
Reeks:Cancer Treatment and Research Communications
Onderwerpen:
Colorectal cancer
Panitumumab
Cetuximab
Third-line
Refractoriness
Online toegang:http://www.sciencedirect.com/science/article/pii/S246829422500005X

Internet

http://www.sciencedirect.com/science/article/pii/S246829422500005X

Gelijkaardige items